Literature DB >> 556552

An MSV-specific subgenomic mRNA in MSV-transformed G8-124 cells.

D J Donoghue, P A Sharp, R A Weinberg.   

Abstract

An intracellular subgenomic RNA species from MSV-transformed G8-124 cells was characterized by electron microscopy of RNA:cDNA heteroduplexes using long cDNAs both MSV and MuLV. This subgenomic RNA, 3.1 kb long, consisted of 5'-derived sequences of about 0.4 kb joined to 2.7 kb of RNA derived from the 3' end of the RNA genome. The 3'-derived sequences included the residual sequences from the MuLV pol region and the acquired cellular sequences of MSV. The genome of MSV was shown to retain approximately 0.13 kb from the 5' end of the MuLV env region, including sequences which span the point in the MuLV env mRNA. No subgenomic MSV RNA could be detected, however, which consisted of a 5'-derived leader sequence spliced to the retained env region sequences. Nor could a subgenomic MSV RNA be detected in which a 5'-derived leader sequence was joined directly to the acquired cellular sequences. Although its translation products are unknown, the subgenomic MSV RNA was present in preparations of poly(A)+ polysomal RNA, consistent with this RNA functioning as a messenger. The structure of this 3.1 kb MSV subgenomic RNA suggests a possible role in the expression of 3'-encoded MSV information, possibly including transformation-specific sequences.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 556552     DOI: 10.1016/0092-8674(79)90294-0

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  13 in total

1.  Comparative study of different isolates of murine sarcoma virus.

Authors:  D J Donoghue; P A Sharp; R A Weinberg
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Three laboratory strains of spleen focus-forming virus: comparison of their genomes and translational products.

Authors:  S Ruscetti; D Troxler; D Linemeyer; E Scolnick
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

3.  Nucleotide sequence analysis of the transforming region and large terminal redundancies of Moloney murine sarcoma virus.

Authors:  E P Reddy; M J Smith; E Canaani; K C Robbins; S R Tronick; S Zain; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

4.  Expression of the PRC II avian sarcoma virus genome.

Authors:  B Adkins; T Hunter; K Beemon
Journal:  J Virol       Date:  1982-03       Impact factor: 5.103

5.  Nucleotide sequence of the 5' noncoding region and part of the gag gene of Rous sarcoma virus.

Authors:  R Swanstrom; H E Varmus; J M Bishop
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

6.  Demonstration of biological activity and nucleotide sequence of an in vitro synthesized clone of the Moloney murine sarcoma virus mos gene.

Authors:  D J Donoghue
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

7.  Temperature-sensitive splicing defect of ts110 Moloney murine sarcoma virus is virus encoded.

Authors:  R Hamelin; K Kabat; D Blair; R B Arlinghaus
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

8.  Biological activity of cloned Moloney sarcoma virus DNA: Terminally redundant sequences may enhance transformation efficiency.

Authors:  D G Blair; W L McClements; M K Oskarsson; P J Fischinger; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

9.  Molecular cloning of Snyder-Theilen feline leukemia and sarcoma viruses: comparative studies of feline sarcoma virus with its natural helper virus and with Moloney murine sarcoma virus.

Authors:  C J Sherr; L A Fedele; M Oskarsson; J Maizel; G Vande Woude
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

10.  Characterization of reticuloendotheliosis virus strain T DNA and isolation of a novel variant of reticuloendotheliosis virus strain T by molecular cloning.

Authors:  I S Chen; T W Mak; J J O'Rear; H M Temin
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.